Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Share your knowledge and expertise with your regulatory peers by submitting an in-depth, evidence-based article focusing on key areas and emerging issues in the global regulatory landscape.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
RAPS Euro Convergence brings regulatory peers from the EU and worldwide together in one forum to gain insights and exchange ideas on the region's most pressing issues. Register today to attend 10-12 May 2021.
Registration is now open for RAPS Convergence 2021! Gather with the regulatory community 12-15 September for four days of learning, engagement, and excitement.
With contributions from more than 30 authors from seven countries, the new edition incorporates a global overview of the field and is designed to help you get the most out of your regulatory intelligence endeavors.
Regipedia is an interactive resource created to benefit RAPS members with 24/7 access to more than 2,300 regulatory terms.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
The RAPS store will be under maintenance Saturday, 17 April between 5 AM and 12 PM EST. Store functionality may be unavailable at times during this window. We apologize for any inconvenience caused during this time.
Posted 19 January 2012 | By Alexander Gaffney, RAC
As the uproar over the faulty breast implants manufactured by French manufacturer Poly Implant Prothese (PIP) continues to unfold, an unwitting casualty may be the US medical device lobby, which has spent the last several years urging the US Food and Drug Administration (FDA) to loosen regulations to be more in line with EU regulatory standards.
The US medical device lobby, led by an association of medical device manufacturers called AdvaMed, has labeled the way the Center for Devices and Radiological Health (CDRH) regulates devices as inconsistent, inefficient and inadequate. A 2011 study conducted for AdvaMed by the Boston Consulting Group concluded that the EU's system of medical device regulation was superior to the US's when graded on the metrics of recalls, approval times and patient safety.
CDRH's Director, Jeffery Shuren, fired back a month later when he suggested that EU regulators were treating their citizens like "guinea pigs", and highlighted that EU regulators do not require proof of effectiveness before allowing a product to be marketed. The comments started a war of words between US and EU regulators, leading the head of the European Commission's Health and Consumers Department to scold Shuren for trying to "publicly discredit the regulatory system in Europe."
Now, that argument may be moot, as FDA successfully avoids a scandal that is causing consternation in the EU.
Breast implants sold by PIP have been reportedly rupturing at an abnormally high rate, and further reports have indicated that the company used unapproved industrial-grade silicone instead of the approved medical-grade silicone. In an interview Reuters, PIP's lawyer, Yves Haddad claimed that PIP's manufacturing plant had done without inspection until 2010, when French regulatory authorities at AFSSAPS received an anonymous tip that the company was not in compliance with regulations.
In response to public outcry, a number of EU regulatory agencies have come out in support of tougher regulation on medical devices. European Medicines Agency (EMA) Executive Director Guido Rasi, French Health Minister Xavier Bertrand, UK National Health Service (NHS) Secretary Andrew Lansley, and European Commission Health and Consumer Policy Spokesperson Frederic Vincent have all called for tougher regulations on medical device manufacturers.
According to Rasi, this could bring the regulation of medical devices more in to line with the way drugs are currently regulated by EMA. "I see an urgent need to regulate devices at the same level of science and attention as with drugs," said Rasi. Bertrand mirrored those sentiments, while Lansley is launching his own investigation in to the matter with an expert review group led by NHS Medical Director Bruce Keough.
The journal The Lancetcame out last week in support of FDA, noting that regulatory vigilance had spared the public in this case, and calling for other countries to learn from the PIP regulatory crisis.
The debate over medical device regulation in the US may be more difficult now for US device manufacturers, notes Bloomberg. With the deadline for the Medical Device User Fee Act fast approaching, Congress may pause to reconsider how forcefully they wish to press the issue in light of the PIP scandal and other recent device failures in the US.
Tags: AdvaMed, MDUFA, Scandal, Breast Implant, PIP, Latest News, medical device
Regulatory Focus newsletters
All the biggest regulatory news and happenings.